EHA2021 Virtual Congress

Non-Hodgkin Lymphoma: Copanlisib Rituximab Combination May Improve Survival

By

Jonathan Goodman, MPhil

June 11, 2021

Six patients experienced a grade 5 treatment-related adverse event.

Next post in Lymphoma

Infection-Related Outcomes Relative to R-CHOP Dose in Older Patients With Diffuse Large B-Cell Lymphoma